Standardising Care and Treatment of Transthyretin Amyloid Cardiomyopathy
References
- Porcari A, Merlo M, Rapezzi C, Sinagra G. Transthyretin amyloid cardiomyopathy: An uncharted territory awaiting discovery. European Journal Internal Medicine. 2020; 82: 7–15. DOI: 10.1016/j.ejim.2020.09.025
- Rapezzi C, Aimo A, Serenelli M, Barison A, Vergaro G, Passino C, et al. Critical Comparison of Documents From Scientific Societies on Cardiac Amyloidosis: JACC State-of-the-Art Review. Journal American College Cardiology. 2022; 79: 1288–1303. DOI: 10.1016/j.jacc.2022.01.036
- Porcari A, Razvi Y, Masi A, Patel R, Ioannou A, Rauf MU, et al. Prevalence, characteristics and outcomes of older patients with hereditary versus wild-type transthyretin amyloid cardiomyopathy. European Journal Heart Failure. 2023; 25: 515–524. DOI: 10.1002/ejhf.2776
- Patel RK, Ioannou A, Razvi Y, Chacko L, Venneri L, Bandera F, et al. Sex differences among patients with transthyretin amyloid cardiomyopathy – from diagnosis to prognosis. European Journal Heart Failure. 2022; 24: 2355–2363. DOI: 10.1002/ejhf.2646
- Chacko L, Karia N, Venneri L, Bandera F, Passo BD, Buonamici L, et al. Progression of echocardiographic parameters and prognosis in transthyretin cardiac amyloidosis. European Journal Heart Failure. 2022; 24: 1700–1712. DOI: 10.1002/ejhf.2606
- Porcari A, Fontana M, Gillmore JD. Transthyretin cardiac amyloidosis. Cardiovascular Research. 2023; 118: 3517–3535. DOI: 10.1093/cvr/cvac119
- Knight DS, Zumbo G, Barcella W, Steeden JA, Muthurangu V, Martinez-Naharro A, et al. Cardiac Structural and Functional Consequences of Amyloid Deposition by Cardiac Magnetic Resonance and Echocardiography and Their Prognostic Roles. JACC Cardiovascular Imaging. 2019; 12: 823–833. DOI: 10.1016/j.jcmg.2018.02.016
- Ioannou A, Patel RK, Razvi Y, Porcari A, Sinagra G, Venneri L, et al. Impact of Earlier Diagnosis in Cardiac ATTR Amyloidosis Over the Course of 20 Years. Circulation. 2022; 146: 1657–1670. DOI: 10.1161/CIRCULATIONAHA.122.060852
- Rapezzi C, Lorenzini M, Longhi S, Milandri A, Gagliardi C, Bartolomei I, et al. Cardiac amyloidosis: the great pretender. Heart Fail Rev. 2015; 20: 11–124. DOI: 10.1007/s10741-015-9480-0
- Porcari A, Pagura L, Longo F, Sfriso E, Barbati G, Murena L, et al. Prognostic significance of unexplained left ventricular hypertrophy in patients undergoing carpal tunnel surgery. ESC Heart Failure. 2022; 9: 751–760. DOI: 10.1002/ehf2.13606
- Milandri A, Farioli A, Gagliardi C, Longhi S, Salvi F, Curti S, et al. Carpal tunnel syndrome in cardiac amyloidosis: implications for early diagnosis and prognostic role across the spectrum of aetiologies. European Journal Heart Failure. 2020; 22: 507–515. DOI: 10.1002/ejhf.1742
- Garcia-Pavia P, Rapezzi C, Adler Y, Arad M, Basso C, Brucato A, et al. Diagnosis and treatment of cardiac amyloidosis: a position statement of the ESC Working Group on Myocardial and Pericardial Diseases. European Heart Journal. 2021; 42: 1554–1568. DOI: 10.1093/eurheartj/ehab072
- Gillmore JD, Maurer MS, Falk RH, Merlini G, Damy T, Dispenzieri A, et al. Nonbiopsy Diagnosis of Cardiac Transthyretin Amyloidosis. Circulation. 2016; 133: 2404–2412. DOI: 10.1161/CIRCULATIONAHA.116.021612
- Porcari A, Hutt DF, Grigore SF, Quigley A-M, Rowczenio D, Gilbertson J, et al. Comparison of different technetium-99 m-labelled bone tracers for imaging cardiac amyloidosis. European Journal Preventive Cardiology. 2022; 30(3): e4–e6. DOI: 10.1093/eurjpc/zwac237
- Maurer MS, Schwartz JH, Gundapaneni B, Elliott PM, Merlini G, Waddington-Cruz M, et al. Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy. New England Journal Medicine. 2018; 379: 1007–1016. DOI: 10.1056/NEJMoa1805689
https://www.acc.org/Latest-in-Cardiology/Clinical-Trials/2023/08/24/02/29/attribute-cm .- Zhang KW, Stockerl-Goldstein KE, Lenihan DJ. Emerging Therapeutics for the Treatment of Light Chain and Transthyretin Amyloidosis. Translational Science. 2019; 4: 438–448. DOI: 10.1016/j.jacbts.2019.02.002
- Fontana M, Martinez-Naharro A, Chacko L, Rowczenio D, Gilbertson JA, Whelan CJ, et al. Reduction in CMR Derived Extracellular Volume With Patisiran Indicates Cardiac Amyloid Regression. JACC Cardiovascular Imaging. 2021; 14: 189–199. DOI: 10.1016/j.jcmg.2020.07.043
- Gillmore JD, Gane E, Taubel J, Kao J, Fontana M, Maitland ML, et al. CRISPR-Cas9 In Vivo Gene Editing for Transthyretin Amyloidosis. New England Journal Medicine. 2021; 385: 493–502. DOI: 10.1056/NEJMoa2107454
- Honig LS, Barakos J, Dhadda S, Kanekiyo M, Reyderman L, Irizarry M, et al. ARIA in patients treated with lecanemab (BAN2401) in a phase 2 study in early Alzheimer’s disease. Alzheimer’s Dementia. 2023; 9:
e12377 . DOI: 10.1002/trc2.12377 - Garcia-Pavia P, aus dem Siepen F, Donal E, Lairez O, van der Meer P, Kristen AV, et al. Phase 1 Trial of Antibody NI006 for Depletion of Cardiac Transthyretin Amyloid. New England Journal Medicine. 2023; 389: 239–250. DOI: 10.1056/NEJMoa2303765
- Fontana M, Gilbertson J, Verona G, Riefolo M, Slamova I, Leone O, et al. Antibody-Associated Reversal of ATTR Amyloidosis–Related Cardiomyopathy. New England Journal Medicine. 2023; 388: 2199–2201. DOI: 10.1056/NEJMc2304584
- Martinez-Naharro A, Patel R, Kotecha T, Karia N, Ioannou A, Petrie A, et al. Cardiovascular magnetic resonance in light-chain amyloidosis to guide treatment. European Heart Journal. 2022; 43(45): 4722–4735. DOI: 10.1093/eurheartj/ehac363
DOI: https://doi.org/10.5334/gh.1275 | Journal eISSN: 2211-8179
Language: English
Submitted on: Sep 20, 2023
Accepted on: Oct 20, 2023
Published on: Nov 20, 2023
Published by: Ubiquity Press
In partnership with: Paradigm Publishing Services
Publication frequency: 1 issue per year
Keywords:
© 2023 Marianna Fontana, Aldostefano Porcari, Philip N. Hawkins, published by Ubiquity Press
This work is licensed under the Creative Commons Attribution 4.0 License.